Analyst Research Roundup: Tetraphase Pharmaceuticals, Inc. (TTPH), Acasti Pharma Inc. (ACST)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) tinted gains of +7.96% (+0.09 points) to US$1.22. The volume of 1.41 Million shares climbed down over an trading activity of 683.26 Million shares. EPS ratio determined by looking at last 12 month figures is -1.43. Over the same time span, the stock marked US$6.9 as its best level and the lowest price reached was US$1.01. The corporation has a market cap of US$70.92 Million.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)’s earnings per share has been growing at a 43.9 percent rate over the past 5 year when average revenue increase was noted as 4.9 percent. The return on equity ratio or ROE stands at -65.9 percent while most common profitability ratio return on investment (ROI) was -88.7 percent. The company’s institutional ownership is monitored at 44.1 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Acasti Pharma Inc. (NASDAQ:ACST) is worth US$70.32 Million and has recently risen 8.19% to US$0.9. The latest exchange of 0.77 Million shares is below its average trading activity of 1.17 Million shares. The day began at US$0.88 but the price moved to US$0.88 at one point during the trading and finally capitulating to a session high of US$0.88. The stock tapped a 52-week high of US$1.8 while the mean 12-month price target for the shares is US$2.52.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 0.75%, it carries an earnings per share ratio of -1.22.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.5.